Epigenetic targeting in pancreatic cancer

Abstract The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years it became evident that deregulation of epigenetic mechanisms plays an important role in pa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2014-06, Vol.40 (5), p.656-664
Hauptverfasser:	van Kampen, Jasmijn G.M, Marijnissen-van Zanten, Monica A.J, Simmer, Femke, van der Graaf, Winette T.A, Ligtenberg, Marjolijn J.L, Nagtegaal, Iris D
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biological and medical sciences Clinical Trials as Topic DNA Methylation - drug effects DNA Methylation - genetics DNA methyltransferase inhibitor Epigenesis, Genetic - drug effects Epigenesis, Genetic - genetics Epigenetics Female Forecasting Gastroenterology. Liver. Pancreas. Abdomen Gene Expression Regulation, Neoplastic Hematology, Oncology and Palliative Medicine Histone deacetylase inhibitor Histone Deacetylase Inhibitors - therapeutic use Histone methyltransferase inhibitor Histone-Lysine N-Methyltransferase - antagonists & inhibitors Histone-Lysine N-Methyltransferase - therapeutic use Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences MicroRNA MicroRNAs - drug effects MicroRNAs - genetics Molecular Targeted Therapy - methods Molecular Targeted Therapy - trends Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Pharmacology. Drug treatments Therapy Treatment Outcome Tumor Microenvironment - drug effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years it became evident that deregulation of epigenetic mechanisms plays an important role in pancreatic carcinogenesis. This review focuses on the exploitation of drugs that alter histone modifications, DNA methylation and microRNA expression as options for the treatment of pancreatic cancer.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2013.12.002